Entering text into the input field will update the search result below

Scynexis completes enrollment in second pivotal study of ibrexafungerp

Feb. 13, 2020 10:20 AM ETSCYNEXIS, Inc. (SCYX) StockSCYXBy: Douglas W. House, SA News Editor10 Comments
  • SCYNEXIS (SCYX +1.4%) has completed the enrollment of 455 subjects in a second Phase 3 clinical trial, VANISH-306, evaluating ibrexafungerp, a broad spectrum antifungal, for the treatment of women with vaginial yeast infections.
  • A sister Phase 3, VANISH-303, was successful.
  • Assuming a positive outcome from the second study, it expects to file a U.S. marketing application in H2.

Recommended For You

About SCYX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SCYX--
SCYNEXIS, Inc.